Northwest Biotherapeutics (NWBO) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$16.9 million.
- Northwest Biotherapeutics' Income from Continuing Operations fell 35.54% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 541.68%. This contributed to the annual value of -$74.3 million for FY2024, which is 2226.54% down from last year.
- As of Q3 2025, Northwest Biotherapeutics' Income from Continuing Operations stood at -$16.9 million, which was down 35.54% from -$16.6 million recorded in Q2 2025.
- In the past 5 years, Northwest Biotherapeutics' Income from Continuing Operations registered a high of -$11.7 million during Q3 2021, and its lowest value of -$22.5 million during Q2 2022.
- Its 5-year average for Income from Continuing Operations is -$16.8 million, with a median of -$16.9 million in 2024.
- Examining YoY changes over the last 5 years, Northwest Biotherapeutics' Income from Continuing Operations showed a top increase of 7818.48% in 2021 and a maximum decrease of 14848.66% in 2021.
- Quarter analysis of 5 years shows Northwest Biotherapeutics' Income from Continuing Operations stood at -$11.8 million in 2021, then tumbled by 64.0% to -$19.4 million in 2022, then rose by 15.54% to -$16.4 million in 2023, then dropped by 28.09% to -$21.0 million in 2024, then increased by 19.28% to -$16.9 million in 2025.
- Its Income from Continuing Operations was -$16.9 million in Q3 2025, compared to -$16.6 million in Q2 2025 and -$18.9 million in Q1 2025.